Pareto Securities Healthcare Conference: Orexo believes that nasal delivery is superior to other modalities for most uses - they plan to file their naloxone program with FDA immanently

<p>CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Orexo also has plans for a nasal spray GLP and vaccines.</p>